The Korean Journal of Nuclear Medicine (대한핵의학회지)

The Korean Society of Nuclear Medicine (대한핵의학회)
권호 표지

Comparison of the Uptakes of $^{99m}Tc-sestamibi\;and\;^{99m}Tc-tetrofosmin$ in Cancer Cell Lines Expressing Multidrug Resistance

다약제내성 발현 암세포에서 $^{99m}Tc-sestamibi$와 $^{99m}Tc-tetrofosmin$ 섭취의 비교

  • Yoo, Jeong-Ah (Department of Nuclear Medicine, Kyunkpook National University School of Medicine) ;
  • Chung, Shin-Young (Department of Nuclear Medicine, Kyunkpook National University School of Medicine) ;
  • Seo, Myeng-Rang (Department of Nuclear Medicine, Kyunkpook National University School of Medicine) ;
  • Kwak, Dong-Suk (Department of Nuclear Medicine, Kyunkpook National University School of Medicine) ;
  • Ahn, Byeong-Cheol (Department of Nuclear Medicine, Kyunkpook National University School of Medicine) ;
  • Lee, Kyu-Bo (Department of Nuclear Medicine, Kyunkpook National University School of Medicine) ;
  • Lee, Jae-Tae (Department of Nuclear Medicine, Kyunkpook National University School of Medicine)
  • 유정아 (경북대학교 의과대학 핵의학교실) ;
  • 정신영 (경북대학교 의과대학 핵의학교실) ;
  • 서명랑 (경북대학교 의과대학 핵의학교실) ;
  • 곽동석 (경북대학교 의과대학 핵의학교실) ;
  • 안병철 (경북대학교 의과대학 핵의학교실) ;
  • 이규보 (경북대학교 의과대학 핵의학교실) ;
  • 이재태 (경북대학교 의과대학 핵의학교실)
  • Published : 2003.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: Cellular uptakes of $^{99m}Tc-sestamibi(MIBI)\;and\;\;^{99m}Tc-tetrofosmin$ into cancer cell lines expressing multidrug resistance(MDR) were investigated and compared. The effects of verapamil and cyclosporin A, well-known multidrug resistant reversing agents, on cellular uptakes of both tracers were also compared. Materials and Methods: Doxorubicin-resistant HCT15/CL02 human colorectal cell and doxorubicin-resistant K562(Adr) and vincristine-resistant K562(Vcr) human leukemic cells were studied. RT-PCR analysis was used for the detection of mdr1 mRNA expression. MDR-reversal effects with verapamil and cyclosporine A were evaluated at different drug concentrations after incubation with MIBI and tetrofosmin for 1, 15, 30, 45 and 60 min, using single-cell suspensions at $1{\times}10^6cells/ml$ incubated at $37^{\circ}C$. Radioactivity in supernatants and pellets were measured with gamma well counter. Results: The cellular uptakes of MIBI and tetrofosmin in K562(Adr) and K562(Vcr) were lower than those of parental K562 cell. In HCT15/CL02 cells and K562(Adr) cells, there were no significant difference in cellular uptakes of both tracers, but cellular uptake of MIBI was higher than that of tetrofosmin in K562(Vcr) cells. Coincubation with verapamil resulted in a increase In cellular uptakes of MIBI and tetrofosmin. Verapamil increased cellular uptakes of MIBI and tetrofosmin by HCT15/CL02 cell by 11.9- and 6.8-fold, by K562(Adr) cell by 14.3- and 8-fold and by K562(Vcr) cell by 7- and 5.7-fold in maximum, respectively. Cyciosporin A increased cellular uptakes of MIBI and tetrofosmin by HCT15/CL02 cell by 10- and 2.4-fold, by K562(Adr) cell by 44- and 13-fold and by K562(Vcr) cell by 18.8- and 11.8-fold in maximum, respectively Conclusion: Taking together, MIBI and tetrofosmin are considered as suitable radiopharmaceuticals for defecting multidrug resistance. However, MIBI seems to be a better tracer than tetrofosmin for evaluating MDR reversal effect of the modulators. Since cellular uptakes of both tracers might differ in different cell types, further experiments regarding differences in cellular uptakes between cell types should be explored.

목적: 다약제내성이 유발된 암세포에서 $^{99m}Tc-sestamibi$와 $^{99m}Tc-tetrofosmin$의 암세포 내 섭취정도를 비교하고 다약제내성 극복제로 잘 알려진 verapamil 과 cyclosporin A 처리에 의한 두 방사성 의약품의 암세포 내 섭취정도를 비교해 보았다. 재료 및 방법: Doxorubicin으로 다약제내성이 유발된 HCT15/CL02 대장암 세포와 doxorubicin과 vincristine으로 다약제내성을 유발시킨 K562(Adr)과 K562(Vcr) 백혈병 세포를 사용하였다. 다약제내성의 발현은 RT-PCR로 증명하였으며, verapamil은 1, 10, 50, 100, 200 ${\mu}M$의 농도로, cyclosporin A는 0.1, 10, 50, 100 ${\mu}M$의 농도로 각각 사용하였다. MIBI와 tetrofosmin의 암세포내 섭취는 $37^{\circ}C$에서 $1{\times}10^{6}cells/ml$ 농도의 단일세포 부유상태에서 1, 15, 30, 45, 60분 간격으로 배양하여 각 시간대별로 상층액과 침전물을 분리하여 각각의 방사능을 감마 계수기로 측정하였다. 결과: 다약제내성이 발현된 암세포에서는 모세포에 비하여 MIBI와 tetrofosmin의 섭취가 감소되었다. 두 방사성약품의 섭취정도는 HCT15/CL02세포와 K562(Adr)세포에서는 유의한 차이가 없었으나, K562(Vcr)세포에서는 MIBI가 tetrofosmin보다 다소 높았다. Verapamil과 cyclosporin A를 처리하였을 때 MIBI와 tetrofosmin의 섭취율은 기저치보다 모두 증가하였고, verapamil 에 의한 MIBI와 tetrofosmin의 섭취율(30분)을 기저치(30분)와 비교해 본 결과 HCT15/CL02 세포에서($100{\mu}M$)는 각각 11.9배와 6.8배, K562(Adr) 세포에서($50{\mu}M$)는 각각 14.3배와 8배, K562(Vcr) 세포에서($10{\mu}M$)는 각각 7배와 5.7배 증가하였다. Cyclosporin A에 의한 MIBI와 tetrofosmin의 섭취율(30분)을 기저치(30분)와 비교해 본 결과 HCT15/CL02세포에서($50{\mu}M$)는 각각 10배와 2.4배, K562(Adr)세포에서($50{\mu}M$)는 각각 44배와 13배, K562(Vcr)세포에서($10{\mu}M$)는 각각 18.8배와 11.8배 증가하여, MIBI의 섭취율이 tetrofosmin보다 1.2배에서 4배정도 높게 나타났다. 결론: 이러한 결과로 보아 MIBI와 tetrofosmin은 다약제내성의 발현을 평가할 수 있는 방사성의약품으로 판단되며, 다약제내성 극복제의 효능평가에는 MIBI가 tetrofosmin보다 더 우수할 것으로 사료되나, 세포추에 따른 차이가 있을 수 있으므로 보다 많은 세포주에서의 추가적인 연구가 필요할 것이다.

Keywords

References

  1. Shen DW, Fojo A, Chin JE, Roninson IB, Richert N, Pastan I. Human multidrug-resistant cell lines: Increased mdr1 expression can precede gene amplification. Science 1986;232:643-5
  2. Piwnica-Worms D, Chiu ML, Budding M, Kronauge JF, Kramer RA, Croop JM Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Res 1993;53:977-84
  3. Breuninger LM, Paul S, Gaughan K, Miki T, Chan A, Aaronson SA. Expression of multidrug resistance associated protein with increased drug efflux and altered intracellular drug distribution. Cancer Res 1995;55: 5342-7
  4. Kostakoglu L, Elahi N, Kiratli P, Ruacan S, Sayek I, Baltali E. Clinical validation of the influence of P-glycoprotein on technetium-99m-sestamibi uptake in malignant tumors. J Nucl Med 1997;38:1003-8
  5. Cordobes MD, Starzec A, Delmon-Moingeon L, Blanchot C, Kouyoumdjian Je, Prevost G, et al. Technetium-99m-sestamibi uptake by human benign and malignant breast tumor cells: correlation with mdr gene expression. J Nucl Med 1996;37:286-9
  6. Taki J, Sumiya H, Asada N, Veda Y, Tsuchiya H, Tonami N. Assessment of P-glycoprotein in patients with malignant bone and soft-tissue tumors using technetium-99m-MIBI scintigraphy. J Nucl Med 1998;39: 1179-84
  7. Cayre A, Moins N, Finat-Duclos F, Verrelle P, Maublant J. Comparison between technetium-99m-sestamibi and H-3-daunomycin myocardial cellular retention in vitro. J Nucl Med 1997;38:1674-7
  8. Kao CH, Ho YJ, Shen YY, Lee JK. Evaluation of chemotherapy response in patients with small cell lung cancer using technetium-99m-tetrofosmin. Anticancer Res 1999;19:2311-5
  9. Lee J. Functional imaging of the multidrug resistance in vivo. Korean J Nucl Med 2001;35:66p-75p
  10. Soman P, Taillefer R, DePuey EG, Udelson JE, Lajiri A. Enhanced detection of reversible perfusion defects by 99m sestamibi compared to Tc-99m tetrofosmin during vasodilator stress SPECT imaging in mild-to-moderate coronary artery disease. J Am Coll Cardiol 2001;37: 458-62
  11. Piwnica-Worms D, Holman BL. Noncardiac applications of hexakis (alkylisonitrile) technetium-99m complexes. J Nucl Med 1990;31:1166-7
  12. Ding HJ, Shiau YC, Tsai SC, Wang JJ, Ho ST, Kao A. Uptake of 99mTc tetrofosmin in lymphoma cell lines: a comparative study with 99mTc sestamibi. Appl Radiat Isot. 2002;56:853-6
  13. Rodrigues M, Chehne F, Kalinowska W, Berghammer P, Zielinki C, Sinzinger H. Uptake of 99mTc-MIBI and 99mTc-tetrofosmin into malignant versus nonmalignant breast cell line. J Nucl Med 2000;41:1495-9
  14. Utsunomiya K, Ballinger JR, Piquette-Miller M, Rauth AM, Tang W, Su ZF, et al. Comparison of the accumulation and efflux kinetics of technetium-99m seestamibi and technetium-99m tetrofosmin in an MRP-expressing tumour cell line. Eur J Nucl Med 2000;27: 1786-92
  15. Perek N, Prevot N, Koumanov F, Frere D, Sabido O, Beauchesne P, et al. Involvement of the glutathione S-conjugate compounds and the MRP protein in Tc-99m-tetrofosmin and Tc-99m-sestamibi uptake in glioma cell lines. Nucl Med Biol 2000;27:299-307
  16. Rodrigues M, Chehne F, Kalinowaka W, Zielinski C, Sinzinger H. Comparative $^{99m}Tc$-MIBI, $^{99m}Tc$-tetrofosmin and $^{99m}Tc$-furifosmin uptake in human soft tissue sarcoma cell lines. Eur J Nucl Med 2000;27:1839-43
  17. Choi SU, Kim NY, Choi EJ, Kim KH, Lee CO. Establishment of doxorubicin-resistant subline derived from Hen5 human colorectal cancer cells. Arch Pharm Res 1996;19:342-7
  18. Balliner JR, Hua BW, Berry BW, Firby P, Boxen I. $^{99m}Tc$-sestamibi as an agent for imaging P-glycoproteinmediated multi-drug resistance: in vitro and in vivo studies in a rat breast tumour cell line and its doxorubicin-resistant variant. Nucl Med Commun 1995;16:253-7
  19. Kelly JD, Forster AM, Higley B, Archer CM, Booker FS, Canning LR, et al. Technetium-99m-tetrofosmin as a new radiopharmaceutical for myocardial perfusion imaging. J Nucl Med 1993;34:222-7
  20. Meghdsdi S, Karanikas G, Schlabauer-Wadl H, Jansen B, Chehne F, Rodrigues M, et al. Technetium-99m-tetrofosmin: a new agent for melanoma imaging? Anticancer Res 1998;18:2759-62
  21. Arbab AS, Koizumi K, Toyama K, Arai T, Araki T. Technetium-99m-tetrofosmin, technetium-99m-MIBI and thallium-20l uptake in rat myocardial cells. J Nucl Med 1998;39:266-71
  22. Arbab AS, Koizumi K, Toyama K, Araki T. Uptake of technetium-99m-tetrofosmin, technetium-99m-MIBI and thallium-20l in tumor cell lines. J Nucl Med 1996;37: 1551-6
  23. Chun KA, Lee J, Lee SW, Kang DY, Sohn SK, Lee JK, et al. Effect of multidrug resistance gene-l (mdrl) overexpression on in-vitro uptake of $^{99m}Tc$-sestamibi in murine L1210 leukemia cells. Korean J Nucl Med 1999;33:152-62
  24. Rao VV, Chiu ML, Kronauge JF, Piwnica-Worms D. Expression of recombinant human multidrug resistance P-glycoprotein in insect cells confers decreased accumulation of technetium-99m-sestamibi. J Nucl Med 1994;35:510-5
  25. Piwnica-Worms D, Rao VV, Krounage JF, Croop JM Characterization of multidrug resistance transport function with an organotechnetium cation. Biochemistry 1995;34:12210-20
  26. Rodrigues M, Kalinowska W, Zielinski C, Sinzinger H. Verapamil decreases accumulation of $^{99m}Tc^m$_MIBI and $^{99m}Tc^m$-tetrofosmin in human breast cancer and soft tissue sarcoma cell lines. Nucl Med Commun 2001;22:645-50